SCHEMBL10327031

SCHEMBL10327031

Cc1ccccc1C(O)(c1ccccc1C)C1CCCN1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.59
KDM4E B2RXH2 1/20 0.59
NPC1 O15118 1/20 0.59
CYP1A2 P05177 1/20 0.59
HPGD P15428 1/20 0.59
MAPK1 P28482 1/20 0.59
CYP2C19 P33261 1/20 0.59
RAB9A P51151 1/20 0.59
SCN4A P35499 1/20 0.38
CHRM3 P20309 4/20 0.38
HTR2C P28335 5/20 0.38
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
MAPT P10636 1/20 0.34
LMNA P02545 1/20 0.33
HRH1 P35367 1/20 0.33
SCN1A P35498 1/20 0.33
SCN2A Q99250 1/20 0.33
SCN3A Q9NY46 1/20 0.33
CHRM2 P08172 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441061 1.00 CYP2D6 (0.59) CYP2D6KDM4ENPC1CYP1A2HPGD
SCHEMBL10326303 1.00 CYP2D6 (0.59) CYP2D6KDM4ENPC1CYP1A2HPGD
SCHEMBL10326551 0.83 KDM4E (0.46) CYP2D6KDM4ENPC1CYP1A2HPGD
SCHEMBL12295123 0.82 KDM4E (0.45) CYP2D6KDM4ENPC1CYP1A2HPGD
SCHEMBL17676890 0.81 KDM4E (0.44) CYP2D6KDM4ENPC1CYP1A2HPGD
SCHEMBL13539487 0.80 KDM4E (0.55) CYP2D6KDM4ENPC1CYP1A2HPGD
SCHEMBL604858 0.78 CYP2D6 (0.56) CYP2D6KDM4ENPC1CYP1A2HPGD
SCHEMBL10326923 0.78 CYP2D6 (0.60) CYP2D6KDM4ENPC1CYP1A2HPGD
SCHEMBL6441272 0.78 CYP2D6 (0.60) CYP2D6KDM4ENPC1CYP1A2HPGD
SCHEMBL10326637 0.78 CYP2D6 (0.60) CYP2D6KDM4ENPC1CYP1A2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217204-B2 Catalyst for asymmetric hydrogenation TAKASAGO INTERNATIONAL CORPORATION (JP) 2012-07-10 US disclosed
US-20100324338-A1 CATALYST FOR ASYMMETRIC HYDROGENATION TAKASAGO INTERNATIONAL CORPORATION (JP) 2010-12-23 US disclosed
WO-2010140636-A1 ASYMMETRIC HYDROGENATION CATALYST 高砂香料工業株式会社 (JP) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324338-A1 CATALYST FOR ASYMMETRIC HYDROGENATION H1-0, H1-5, ADH5 CYP2D6 1125/4885KDM4E 4195/4885NPC1 2005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.